Literature DB >> 18084005

Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells.

Dong Woo Kang1, Mi Hee Park, Young Jun Lee, Hyung Sik Kim, Taeg Kyu Kwon, Won-Sang Park, Do Sik Min.   

Abstract

Despite its importance in cell proliferation and tumorigenesis, very little is known about the molecular mechanism underlying the regulation of phospholipase D (PLD) expression. PLD isozymes are significantly co-overexpressed with cancer marker genes in colorectal carcinoma. Phorbol 12-myristate 13-acetate (PMA) treatment, as a mitogenic signal in colon cancer cells, selectively increases PLD1 expression in transcription and post-transcription. Moreover, experiments using intraperitoneal injection of PMA into mice showed selective PLD1 induction in the intestine and lung tissues, which suggests its physiological relevance in vivo. Therefore, we have undertaken a detailed analysis of the effects of PMA on the promoter activity of PLD genes. Protein kinase C inhibitors, but not a protein kinase A inhibitor, were found to suppress the up-regulation of PLD1 but not PLD2. Dominant-negative mutants of Ras, Raf, and MEK suppressed the induction and activity of PLD1. Moreover, depletion of the supposedly involved proteins reduced the endogenous PLD1 protein level. An important role for NFkappaB as a downstream target of ERK in PMA-induced PLD1 induction was also demonstrated using the inhibitor, small interfering RNA, chromatin immunoprecipitation assay, and site-specific mutagenesis. Furthermore, inhibitors of these signaling proteins and depletion of PLD1 suppressed PMA-induced matrix metalloproteinase-9 secretion and PLD1 induction. In conclusion, we demonstrate for the first time that induction of PLD1 through a protein kinase C/Ras/ERK/NFkappaB-dependent pathway is involved in the secretion of matrix metalloproteinase-9 in colorectal cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084005     DOI: 10.1074/jbc.M707416200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells.

Authors:  Dong Woo Kang; Gyesik Min; Do Yoon Park; Ki Whan Hong; Do Sik Min
Journal:  Exp Mol Med       Date:  2010-08-31       Impact factor: 8.718

Review 2.  Mammalian phospholipase D physiological and pathological roles.

Authors:  X Peng; M A Frohman
Journal:  Acta Physiol (Oxf)       Date:  2011-05-28       Impact factor: 6.311

Review 3.  Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.

Authors:  Wenjuan Su; Qin Chen; Michael A Frohman
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

4.  Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells.

Authors:  Dong Woo Kang; Do Sik Min
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

Review 5.  Phospholipase signalling networks in cancer.

Authors:  Jong Bae Park; Chang Sup Lee; Jin-Hyeok Jang; Jaewang Ghim; Youn-Jae Kim; Sungyoung You; Daehee Hwang; Pann-Ghill Suh; Sung Ho Ryu
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

Review 6.  Functional regulation of phospholipase D expression in cancer and inflammation.

Authors:  Dong Woo Kang; Kang-Yell Choi; Do Sik Min
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

7.  Phospholipase D1 has a pivotal role in interleukin-1β-driven chronic autoimmune arthritis through regulation of NF-κB, hypoxia-inducible factor 1α, and FoxO3a.

Authors:  Dong Woo Kang; Mi-Kyung Park; Hye-Joa Oh; Dong-Gun Lee; Sung-Hwan Park; Kang-Yell Choi; Mi-La Cho; Do Sik Min
Journal:  Mol Cell Biol       Date:  2013-05-20       Impact factor: 4.272

8.  Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.

Authors:  Sarah A Scott; Paige E Selvy; Jason R Buck; Hyekyung P Cho; Tracy L Criswell; Ashley L Thomas; Michelle D Armstrong; Carlos L Arteaga; Craig W Lindsley; H Alex Brown
Journal:  Nat Chem Biol       Date:  2009-01-11       Impact factor: 15.040

9.  The IGF-I receptor can alter the matrix metalloproteinase repertoire of tumor cells through transcriptional regulation of PKC-{alpha}.

Authors:  Shun Li; Donglei Zhang; Long Yang; Julia V Burnier; Ni Wang; Rongtuan Lin; Eunice R Lee; Robert I Glazer; Pnina Brodt
Journal:  Mol Endocrinol       Date:  2009-10-23

10.  Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells.

Authors:  Dong Woo Kang; Ji Young Lee; Deuk Hee Oh; Seon Yang Park; Tae Min Woo; Mi Kyoung Kim; Mi Hee Park; Young Hoon Jang; Do Sik Min
Journal:  Exp Mol Med       Date:  2009-09-30       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.